Literature DB >> 25888599

Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer.

Ning Wang1, Freyja Docherty1, Hannah K Brown1, Kim Reeves1, Anne Fowles1, Michelle Lawson1, Penelope D Ottewell1, Ingunn Holen1, Peter I Croucher1, Colby L Eaton2.   

Abstract

This study aimed to identify subpopulations of prostate cancer cells that are responsible for the initiation of bone metastases. Using rapidly dividing human prostate cancer cell lines, we identified mitotically quiescent subpopulations (<1%), which we compared with the rapidly dividing populations for patterns of gene expression and for their ability to migrate to the skeletons of athymic mice. The study used 2-photon microscopy to map the presence/distribution of fluorescently labeled, quiescent cells and luciferase expression to determine the presence of growing bone metastases. We showed that the mitotically quiescent cells were very significantly more tumorigenic in forming bone metastases than fast-growing cells (55 vs. 15%) and had a unique gene expression profile. The quiescent cells were not uniquely stem cell like, with no expression of CD133 but had the same level expression of other putative prostate stem cell markers (CD44 and integrins α2/β1), when compared to the rapidly proliferating population. In addition, mitotic quiescence was associated with very high levels of C-X-C chemokine receptor type 4 (CXCR4) production. Inhibition of CXCR4 activity altered the homing of quiescent tumor cells to bone. Our studies suggest that mitotic dormancy is a unique phenotype that facilitates tumor cell colonization of the skeleton in prostate cancer. © FASEB.

Entities:  

Keywords:  CXCR4; cell quiescence; metastatic niche

Mesh:

Substances:

Year:  2015        PMID: 25888599     DOI: 10.1096/fj.14-266379

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  21 in total

Review 1.  Cellular determinants and microenvironmental regulation of prostate cancer metastasis.

Authors:  Kiera Rycaj; Hangwen Li; Jianjun Zhou; Xin Chen; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2017-04-11       Impact factor: 15.707

Review 2.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

3.  Confocal/two-photon microscopy in studying colonisation of cancer cells in bone using xenograft mouse models.

Authors:  Gloria Allocca; Anjali P Kusumbe; Saravana K Ramasamy; Ning Wang
Journal:  Bonekey Rep       Date:  2016-12-07

4.  Tumor dormancy in bone.

Authors:  Vera Mayhew; Tolu Omokehinde; Rachelle W Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-29

Review 5.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

Review 6.  The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.

Authors:  Christina J Turner; Claire M Edwards
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

7.  The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.

Authors:  H Endo; J Okami; H Okuyama; Y Nishizawa; F Imamura; M Inoue
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

Review 8.  Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.

Authors:  Frank C Cackowski; Russell S Taichman
Journal:  Bone       Date:  2018-02-26       Impact factor: 4.398

9.  Identification of Genes Regulating Breast Cancer Dormancy in 3D Bone Endosteal Niche Cultures.

Authors:  Julie McGrath; Louis Panzica; Ryan Ransom; Henry G Withers; Irwin H Gelman
Journal:  Mol Cancer Res       Date:  2019-01-16       Impact factor: 5.852

10.  Breast cancer cells and bone marrow mesenchymal stromal cells: a regulated modulation of the breast tumor in the context of immune response.

Authors:  Mehdi Najar; Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Fabrice Journe; Laurence Lagneaux
Journal:  Inflamm Res       Date:  2016-10-25       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.